nach oben

Erschienen in:

22.04.2022 | Research Article

⁶⁸Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR-β Expression in Renal Cell Carcinoma Patients

verfasst von: Jie Gao, Longxiyu Meng, Qinfeng Xu, Xiaozhi Zhao, Yongming Deng, Yao Fu, Suhan Guo, Kuiqiang He, Jiong Shi, Feng Wang, Shiwei Zhang, Hongqian Guo

Erschienen in: Molecular Imaging and Biology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Response prediction is necessary for renal cell carcinoma (RCC) tumors. We aim to evaluate parameters derived from ⁶⁸ Ga-PSMA-11 PET/CT images for prediction of pathological VEGFR-2/PDGFR-β expression of primary RCC tumors.

Methods

Forty-eight RCC patients were retrospectively enrolled with preoperative ⁶⁸ Ga-PSMA-11 PET/CT scan and surgical specimen. Radiological parameters including tumor diameter, mean CT value, and maximal standard uptake value (SUV_max) were derived from PET/CT images and pathological VEGFR-2/PDGFR-β/PSMA expression were identified with immunohistochemistry. Mann–Whitney U test was performed for continuous variables and the chi-square test for categorical variables. ROC was used for determining the effectiveness of preoperative parameters in differentiating VEGFR-2/PDGFR-β expression. Univariate and multivariate logistic regression analyses were performed for significant parameters to predict VEGFR-2 & PDGFR-β co-expression.

Results

Of the 48 tumors, 25 (52.1%) harbored positive VEGFR-2 expression, 28 (58.3%) harbored positive PDGFR-β expression, and 24 (50%) were both VEGFR-2 positive and PDGFR-β positive. SUV_max significantly differed by subgroups of VEGFR-2/PDGFR-β expression (both P < 0.001). SUV_max demonstrated superior performance for differentiating VEGFR-2 & PDGFR-β co-expression (positive vs. negative), with area under the curve 0.87 (95% CI 0.78–0.96, P < 0.001), sensitivity 93% and specificity 78%. Moreover, SUV_max was identified as the significant predictor for VEGFR-2 & PDGFR-β co-expression (odds ratio 4.01, 95% CI 1.99–8.08, P < 0.001). Concordant with radiological findings with ⁶⁸ Ga-PSMA-11 PET/CT, pathological PSMA staining intensity was significantly higher in both VEGFR-2-positive tumor and PDGFR-β-positive tumor (P = 0.009 and P < 0.001, respectively).

Conclusion

⁶⁸ Ga-PSMA-11 PET/CT could effectively identify pathological VEGFR-2/PDGFR-β expression of primary RCC tumors, which may help with selection of mRCC patients suitable for TKIs treatment.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442CrossRefPubMed

Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J et al (2019) Epidemiology of renal cell carcinoma. Eur Urol 75:74–84. https://doi.org/10.1016/j.eururo.2018.08.036CrossRefPubMed

Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (Oxford, England: 1990) 46:765–81. https://doi.org/10.1016/j.ejca.2009.12.014CrossRef

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540. https://doi.org/10.1200/jco.1999.17.8.2530CrossRefPubMed

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M et al (2017) Renal cell carcinoma. Nat Rev Dis Primers 3:17009. https://doi.org/10.1038/nrdp.2017.9CrossRefPubMedPubMedCentral

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20:1370–1385. https://doi.org/10.1016/s1470-2045(19)30413-9CrossRefPubMedPubMedCentral

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829–841. https://doi.org/10.1056/NEJMoa2026982CrossRefPubMedPubMedCentral

Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12:7215–7220. https://doi.org/10.1158/1078-0432.ccr-06-2254CrossRefPubMed

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134. https://doi.org/10.1056/NEJMoa060655CrossRefPubMed

10.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124. https://doi.org/10.1056/NEJMoa065044CrossRefPubMed

11.

Casper J, Schumann-Binarsch S, Köhne CH (2013) Pazopanib versus sunitinib in renal cancer. N Engl J Med 369:1969. https://doi.org/10.1056/NEJMc1311795CrossRefPubMed

12.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England) 378:1931–1939. https://doi.org/10.1016/s0140-6736(11)61613-9CrossRef

13.

Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473–1482. https://doi.org/10.1016/s1470-2045(15)00290-9CrossRefPubMed

14.

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814–1823. https://doi.org/10.1056/NEJMoa1510016CrossRefPubMedPubMedCentral

15.

Mollica V, Di Nunno V (2019) Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. Cancers. 11. https://doi.org/10.3390/cancers11060830.

16.

Terakawa T, Miyake H, Kusuda Y, Fujisawa M (2013) Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol 31:493–498. https://doi.org/10.1016/j.urolonc.2011.02.012CrossRefPubMed

17.

Lee JN, Chun SY, Ha YS, Choi KH, Yoon GS, Kim HT et al (2016) Target molecule expression profiles in metastatic renal cell carcinoma: development of individual targeted therapy. Tissue Eng Regen Med 13:416–427. https://doi.org/10.1007/s13770-016-9088-zCrossRefPubMedPubMedCentral

18.

Jiang W, Wang D, Liu X, Zheng W, Wen L, Shi H et al (2021) PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy. Urol Oncol 39:78.e9-.e16. https://doi.org/10.1016/j.urolonc.2020.09.012CrossRef

19.

Mokoala K, Lawal I (2021) PSMA Theranostics: Science and Practice. Cancers. 13. https://doi.org/10.3390/cancers13153904.

20.

Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bogemann M, et al (2018) Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. 45:860-77. https://doi.org/10.1007/s00259-017-3922-y

21.

Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB et al (2018) Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med 59:871–877. https://doi.org/10.2967/jnumed.117.203570CrossRefPubMed

22.

Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B et al (2018) Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol 199:370–377. https://doi.org/10.1016/j.juro.2017.08.079CrossRefPubMed

23.

Evangelista L, Basso U, Maruzzo M, Novara G (2020) The role of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for the evaluation of renal cancer. Eur Urol Focus 6:146–150. https://doi.org/10.1016/j.euf.2018.08.004CrossRefPubMed

24.

Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H et al (2019) A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imag Biol 21:799–807. https://doi.org/10.1007/s11307-018-01307-0CrossRef

25.

Mittlmeier LM, Unterrainer M, Todica A, Cyran CC, Rodler S, Bartenstein P et al (2020) PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 47:2216–2217. https://doi.org/10.1007/s00259-019-04636-6CrossRefPubMed

26.

Mittlmeier LM, Unterrainer M, Rodler S, Todica A, Albert NL, Burgard C et al (2021) (18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. Eur J Nucl Med Mol Imaging 48:2031–2037. https://doi.org/10.1007/s00259-020-05165-3CrossRefPubMed

27.

Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029CrossRefPubMed

28.

Delahunt B, Eble JN, Egevad L (2019) Grading of renal cell carcinoma. Histopathology 74:4–17. https://doi.org/10.1111/his.13735CrossRefPubMed

29.

Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E et al (2013) Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol 24:2409–2414. https://doi.org/10.1093/annonc/mdt219CrossRefPubMed

30.

Gao J, Xu Q, Fu Y, He K, Zhang C, Zhang Q et al (2021) Comprehensive evaluation of (68)Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 48:561–569. https://doi.org/10.1007/s00259-020-04916-6CrossRefPubMed

Titel: 68Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR-β Expression in Renal Cell Carcinoma Patients
verfasst von: Jie Gao
Longxiyu Meng
Qinfeng Xu
Xiaozhi Zhao
Yongming Deng
Yao Fu
Suhan Guo
Kuiqiang He
Jiong Shi
Feng Wang
Shiwei Zhang
Hongqian Guo
Publikationsdatum: 22.04.2022
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 5/2022
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-022-01725-1

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

⁶⁸Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR-β Expression in Renal Cell Carcinoma Patients